ArticleEuropean journal of medical research2025
A combined study of pharmacodynamics and pharmacokinetics of methamphetamine and its metabolite in male mice.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMethamphetamine (METH) is typically characterized as a potent dependent psychostimulant. Various behavioral models have been used to study METH drug dependence. The objective of this study was to determine the time period during which the neuropharmacological effects of METH are most pronounced, through a combined study of pharmacodynamics and pharmacokinetics.
methodsThe present study simultaneously investigated the pharmacodynamics and pharmacokinetics of METH and its metabolite amphetamine (AMP) in mice by measuring the locomotor activity level and the concentrations of METH and AMP in the blood and brain from 5 min to 8 h after administration.
resultsThe pharmacodynamic analysis showed that the mice maintained a high level of activity from 5 min to 1 h after the administration, followed by a significant decrease in activity at 2 h. The pharmacokinetic analysis showed that METH was rapidly absorbed into the blood, and its concentration reached the peak value at 5 min. AMP concentration in blood increased and reached the peak value at 1 h; the concentrations of METH and AMP in the brain both reached the peak value at 30 min.
conclusionsIn terms of pharmacodynamics and pharmacokinetics, the behavioral effects of METH on mice are most obvious within 1 h, at most 2 h, after administration, which can thus be considered a preferred time period to study the neuropharmacology effects of METH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.